AlvireX: A game-changing translational drug screening platform to revolutionize drug development against respiratory viral infections

• Unité de recherche: INNOSUISSE
• Numéro de projet: 53709.1 IP-LS
• Titre du projet anglais: AlvireX: A game-changing translational drug screening platform to revolutionize drug development against respiratory viral infections

Description succincte (Allemand)

AlvireX: A game-changing translational drug screening platform to revolutionize drug development against respiratory viral infections

Description succincte (Anglais)

AlvireX: A game-changing translational drug screening platform to revolutionize drug development against respiratory viral infections

Résumé des résultats (Abstract) (Allemand)

The consortium will develop AlvireX - a novel drug screening platform that will accelerate and improve drug development for respiratory viruses, such as SARS-CoV-2. Here, we will deliver the first AlvireX kit tailored to COVID-19 research, which will be ready to enter the market in Q1 2023.